The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The COVID-19 Crisis: Uncharted Waters & the ACR’s Response

The COVID-19 Crisis: Uncharted Waters & the ACR’s Response

April 15, 2020 • By Ellen M. Gravallese, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Singer Jimmy Dean reportedly once said, “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” The COVID-19 pandemic has required us as rheumatologists to adjust our sails multiple times. We have had to rethink many of the ways in which we interact with our worried patients to provide the highest quality care, along with practical and emotional support, and to do it all safely during these extraordinary times.

You Might Also Like
  • Join the ACR COVID-19 Clinical Guidance Town Hall: May 6
  • Forging New Ways to Teach in Response to COVID-19: Q&A with Anisha Dua, MD, MPH
  • CMS Relaxes Telehealth Restrictions
Explore This Issue
May 2020
Also By This Author
  • ACR President Ellen Gravallese, MD, Says Farewell

At the ACR, we have been searching for ways to help our members adjust their sails and assist them in navigating these challenges. I would like to underscore some of the resources that have been developed and are currently available on the ACR website, and highlight the ways in which the ACR has been advocating on behalf of patients and providers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Early in the COVID-19 crisis, the ACR Executive Committee established two task forces to support our members and the entire rheumatology community. These are the Practice and Advocacy Task Force (Chair: Kelly Weselman, MD, FACR; Executive Committee liaison: Douglas White, MD, PhD) and the Clinical Guidance Task Force (Chair: Ted R. Mikuls, MD; Executive Committee liaisons: Kenneth Saag, MD, MSc, and me). These two groups have worked tirelessly to provide information for members and address ongoing needs posed by the pandemic.

Practice & Advocacy Resources
The ACR advocacy team has done a tremendous amount of work in advocating for the availability and proper use of hydroxychloroquine, a drug that is essential for the treatment of lupus and is also used in other rheumatic diseases. Some early evidence suggested this medication holds potential as a possible treatment for COVID-19. This position has led to drug shortages and decreased drug availability for some of our patients. As rheumatologists and rheumatology professionals, we need to advocate for our patients’ access to the drug while clinical trials establish whether hydroxychloroquine is truly effective to treat COVID-19.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Working in conjunction with the American Academy of Dermatology, the Arthritis Foundation and the Lupus Foundation of America, the ACR has released a statement to the White House Coronavirus Task Force and the nation’s governors highlighting issues critical to hydroxychloroquine access. The ACR has also provided a template that medical providers can use to help advocate for appropriate use of hydroxychloroquine during this time.

The Practice and Advocacy Task Force has provided a great deal of information covering specific guidance on practice management issues, including guiding principles for proper resource allocation of medications that may be in high demand during the COVID-19 crisis. In addition to hydroxychloroquine, these include rheumatic disease drugs with potential applications in COVID-19, such as drugs inhibiting interleukin (IL) 1 and IL-6.

Pages: 1 2 3 4 | Single Page

Filed Under: American College of Rheumatology, President's Perspective, Professional Topics Tagged With: COVID-19Issue: May 2020

You Might Also Like:
  • Join the ACR COVID-19 Clinical Guidance Town Hall: May 6
  • Forging New Ways to Teach in Response to COVID-19: Q&A with Anisha Dua, MD, MPH
  • CMS Relaxes Telehealth Restrictions
  • Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.